تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
20.84 US$
+0.47 US$ · +2.31%
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
الإغلاق السابق
20.84 US$
+0.47 US$ · +2.31%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
نطاق اليوم
السعر الحالي 20.84 US$
نطاق 52 أسبوعًا
السعر الحالي 20.84 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
47
قيمة عادلة
المشاعر
49
مختلط
المخاطر
52
مخاطر أعلى من المعتاد
الزخم
69
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
نطاق اليوم
السعر الحالي 20.84 US$
نطاق 52 أسبوعًا
السعر الحالي 20.84 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 2.72 مليار USD | 2.7 مليار USD | 2.84 مليار USD | 2.84 مليار USD | 3.06 مليار USD |
| تكلفة البضاعة المباعة | 2.3 مليار USD | 2.16 مليار USD | 2.25 مليار USD | 2.11 مليار USD | 2.45 مليار USD |
| الربح الإجمالي | 425.8 مليون USD | 534.2 مليون USD | 590.6 مليون USD | 724.4 مليون USD | 604.4 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 456.4 مليون USD | 560.7 مليون USD | 448.1 مليون USD | 416.1 مليون USD | 303.1 مليون USD |
| نفقات التشغيل | 456.4 مليون USD | 696.1 مليون USD | 558.6 مليون USD | 537.3 مليون USD | 490.1 مليون USD |
| مصاريف الفوائد | 91.4 مليون USD | 123.8 مليون USD | 69.8 مليون USD | 200 ألف USD | 200 ألف USD |
| الاستهلاك والإطفاء | 78 مليون USD | 86.9 مليون USD | 98 مليون USD | 93.6 مليون USD | 166.3 مليون USD |
| الدخل التشغيلي | −30.6 مليون USD | −161.9 مليون USD | 32 مليون USD | 187.1 مليون USD | 114.3 مليون USD |
| صافي الدخل | −986.2 مليون USD | −328.5 مليون USD | −25.2 مليون USD | 186.2 مليون USD | 98 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
